Fewer than 10 per
cent of lung cancer patients survive the disease beyond five years after diagnosis.
The team studied a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per
cent of lung cancer patients.
Not exact matches
The drug erlotinib is prescribed to between 10 — 30 per
cent of patients with non-small cell
lung cancer, which accounts for 85 per
cent of all
lung cancer cases.
The drug erlotinib is prescribed to between 10 - 30 per
cent of patients with non-small cell
lung cancer, which accounts for 85 per
cent of all
lung cancer cases.
One reason is that the majority - 65 - 75 per
cent -
of lung cancer patients are diagnosed when the
cancer has already become aggressive, which makes it more difficult to treat successfully.